Abstract
Background: Metro Mapping is an innovative service design methodology to co-design clinical care paths to support shared decision-making in oncology. We provide a study protocol for a cost-effectiveness analysis (CEA) evaluating health effects and costs of applying Metro Mapping to redesign selected clinical care paths for patients with cancer. Methods: The CEA will be conducted alongside a pre-test–post-test study evaluating the impact of Metro Mapping on decision-making processes and outcomes in selected clinical care paths of patients with melanoma, breast, or prostate cancer in the Netherlands, Denmark, and Spain. In the pre-test phase, patients follow the standard cancer treatment path. In the post-test phase, patients follow a care path redesigned using Metro Mapping. In the CEA, care after Metro Mapping (i.e., post-test) will be evaluated against care before Metro Mapping (i.e., the pre-test). The CEA adopts a societal perspective; health effects and costs will be evaluated alongside selected care paths in both pre- and post-test groups over a time horizon of 36 months corresponding to the study period. Regret after a healthcare decision based on the decision regret scale (inversely reflecting satisfaction) and health-related quality of life based on EQ-5D-5L and EORTC QLU-C10D will be assessed at the beginning and after six months for each care trajectory, in both groups. Direct medical costs will be estimated using resource utilization from electronic medical records and reimbursement prices. Direct non-medical costs and indirect costs will be assessed through a short version of the iMTA Productivity Cost Questionnaire employed at the end of each care trajectory. Main outcomes are absolute total costs, quality-adjusted life years, decision regret/satisfaction, and the incremental cost-effectiveness ratio for the application of Metro Mapping vs. no Metro Mapping. Health effects and costs will be evaluated using descriptive statistics and multivariable statistical methods to account for baseline confounding. Uncertainty will be assessed through deterministic and probabilistic sensitivity analyses. Discussion: This study protocol describes a prospective and systematic CEA alongside a pre-test–post-test study to evaluate the cost-effectiveness of Metro Mapping in selected care paths of three different cancers and countries, making the research process transparent and reproducible. Trial registration: The pre-test–post-test study has been registered in the clinical.gov trial registry (record number: 8423, identifier: NCT06685562, registration date: 12 November 2024).